Ionis Pharmaceuticals IONS Net Operating Loss Carryforwards
Net Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwards.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's net operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's net operating loss carryforwards?
- Ionis Pharmaceuticals (IONS) reported net operating loss carryforwards of $361.06M in Q4 2025.
- What does net operating loss carryforwards mean?
- Past losses that can be used to lower future tax bills.
- How do you interpret net operating loss carryforwards?
- Higher values represent a significant tax shield that can improve future net income and cash flow once the company is profitable.
- How does net operating loss carryforwards compare across companies?
- Common in high-growth or R&D-heavy sectors like biotech where early-stage losses are typical.